STAAR Surgical Reports Mixed Q4, Misses Revenue Estimates as Stock Falls
STAAR SURGICAL CO (NASDAQ:STAA), a developer of implantable lenses for vision correction, reported financial results for its fourth quarter and full fiscal year 2025. The company’s earnings release painted a complex picture of operational progress overshadowed by a significant revenue shortfall against Wall Street expectations, leading to a sharp decline in its share price.
Earnings and Revenue Versus Estimates
The market’s primary focus was on the top-line performance for the quarter ended January 2, 2026. STAAR Surgical reported net sales of $57.8 million, which represents a year-over-year increase of 18.1%. However, this figure fell substantially short of analyst consensus estimates, which had anticipated revenue of approximately $76.9 million. This miss of nearly $19 million is a key driver behind the stock's negative reaction.
On the bottom line, the company reported a net loss of $0.37 per share on a GAAP basis. Its non-GAAP adjusted earnings per share (EPS) came in at $0.04. This also missed the analyst estimate for non-GAAP EPS of $0.0583, though the variance here was less dramatic than the revenue miss. The market’s punitive response, with the stock dropping over 9% in after-hours trading and 11.2% on the news day, underscores the weight given to the revenue disappointment.
Market Reaction and Price Action
The immediate market reaction was decisively negative. The stock’s steep decline reflects investor concern over the magnitude of the revenue miss and the underlying causes, which management attributed largely to distributor dynamics in China related to its recently terminated merger deal with Alcon. This drop erases modest gains the stock had posted over the prior month and highlights the high expectations embedded in the share price prior to the report.
Key Takeaways from the Press Release
Beyond the headline misses, management highlighted several important operational developments:
- China Dynamics: The quarter was heavily impacted by inventory movements in China. While "in-market" demand to end-users showed a mid-single-digit recovery for the year and accelerated in Q4, STAAR's reported sales in the region were hurt as sub-distributors, uncertain about the company's future during the Alcon merger talks, returned inventory. With the merger question resolved, leadership expects a return to growth in China for fiscal 2026, aided by the launch of the higher-priced EVO+ ICL.
- Progress on Profitability: The company emphasized disciplined cost management. Excluding one-time merger and restructuring expenses, operating expenses for the full year were reduced by 9.4%. Notably, the Q4 gross margin expanded significantly to 75.7%, up from 64.7% a year ago, benefiting from cost reductions and the ramp-up of Swiss manufacturing.
- Full-Year Context: For fiscal year 2025, total net sales of $239.4 million declined 23.7% year-over-year, heavily influenced by the inventory reduction in China during the first half. However, net sales excluding China grew 6.6% to $161.7 million, indicating underlying strength in other global markets.
- Strong Balance Sheet: The company ended the year with a robust cash position of $187.5 million and no debt, providing financial flexibility as it moves forward independently.
Looking Ahead: Outlook Versus Analyst Forecasts
In their commentary, interim co-CEOs expressed optimism for fiscal 2026, citing a "clear path toward sustained profitability and growth" and expecting "modest growth in in-market volume demand" in China alongside rising average selling prices. This qualitative optimism will now be measured against quantitative analyst models.
Currently, analysts are estimating sales of approximately $320.5 million for the full 2026 fiscal year. For the upcoming first quarter of 2026, the consensus estimates project revenue of $71.7 million and a non-GAAP EPS loss of $0.084. Management did not provide specific quantitative guidance, so investors will closely monitor upcoming quarters to see if the company’s recovery trajectory aligns with these external expectations.
For a detailed breakdown of historical earnings, future estimates, and analyst projections, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer to buy or sell any securities. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
